Company news
Karyopharm Therapeutics Inc. news in 2020
Karyopharm Therapeutics Inc.'s news releases, calls and decks from 2020, newest first.
Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
December 17, 2020
Karyopharm Appoints Michael Mano as Senior Vice President, General Counsel and Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 14, 2020
Karyopharm Announces National Comprehensive Cancer Network® Adds Three XPOVIO® (selinexor) Treatment Regimens to Its Clinical Practice Guidelines in Oncology for Multiple Myeloma
December 10, 2020
Karyopharm Announces Presentation of New XPOVIO® (Selinexor) Data in Patients with Acute Myeloid Leukemia at the American Society of Hematology 2020 Annual Meeting
December 6, 2020
Karyopharm Expands Board of Directors and Executive Leadership Team and Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 30, 2020
Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 3 BOSTON Study Results in The Lancet
November 11, 2020
Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2020 Annual Meeting
November 3, 2020
Karyopharm Announces Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Unresectable Dedifferentiated Liposarcoma
November 1, 2020
Karyopharm to Report Third Quarter 2020 Financial Results on November 2, 2020
October 25, 2020
Karyopharm Announces Selinexor Clinical Data to be Presented at the International Society for Influenza and Other Respiratory Virus Diseases Antiviral Group Virtual Conference on Therapeutics for COVID-19
October 5, 2020
Karyopharm Announces XPOVIO® (selinexor) Clinical Data to be Presented at European Society for Medical Oncology Virtual Congress 2020
September 13, 2020
Karyopharm Therapeutics Appoints Christy J. Oliger to its Board of Directors
August 30, 2020
Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress
August 3, 2020
Karyopharm to Report Second Quarter 2020 Financial Results on August 4, 2020
July 27, 2020
U.S. Food and Drug Administration Accepts Karyopharm’s Supplemental New Drug Application for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy
July 19, 2020
Karyopharm Establishes Partnership with National Cancer Institute to Advance XPOVIO® (selinexor) Research
July 16, 2020
Karyopharm Announces Preliminary Unaudited Second Quarter Product Sales for XPOVIO® (selinexor)
July 13, 2020
Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 2b SADAL Study Results in The Lancet Haematology
June 23, 2020
Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
June 21, 2020
Karyopharm Announces Dosing of First Patient in a Phase 1/2 Study of Selinexor in Combination with Standard of Care Therapy for Patients with Newly Diagnosed or Recurrent Glioblastoma
June 8, 2020
Karyopharm Announces Investor Conference Call to Discuss Phase 3 BOSTON Data To Be Presented at the American Society of Clinical Oncology 2020 Virtual Scientific Program
May 25, 2020
Karyopharm Submits Supplemental New Drug Application to FDA for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy
May 19, 2020
Karyopharm Donates 60,000 Medical Masks Across Massachusetts and the United States in Partnership with Family Reach, Myeloma Crowd and The Leukemia & Lymphoma Society
May 12, 2020
Karyopharm Announces Data from Phase 3 BOSTON Study Selected for Late-Breaking Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program
April 28, 2020
Karyopharm to Report First Quarter 2020 Financial Results on May 5, 2020
April 27, 2020
Karyopharm Announces Dosing of First Patient in Randomized Study Evaluating Low Dose Selinexor in Patients with Severe COVID-19
April 19, 2020
Karyopharm Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
March 16, 2020
Karyopharm Expands Executive Leadership Team with the Appointment of John Demaree as Chief Commercial Officer
March 11, 2020
Karyopharm Therapeutics Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
March 5, 2020
Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock
March 2, 2020
Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock
March 1, 2020
Karyopharm Appoints Richard Paulson to its Board of Directors
February 27, 2020
U.S. Food and Drug Administration Accepts Karyopharm’s Supplemental New Drug Application for XPOVIO® (Selinexor) as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
February 18, 2020
Karyopharm and Promedico, a Member of the Neopharm Group, Enter into an Exclusive Distribution Agreement to Commercialize XPOVIO® (Selinexor) in Israel
February 10, 2020
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 2, 2020
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Product Sales for XPOVIO® (selinexor) and Provides Commercial Update
January 12, 2020
Calls in 2020
Decks in 2020
- Q3 2020 Earnings Presentation
Earnings · 21 slides · Nov 2, 2020
- Technical Presentation (October 2020)
Technical · 17 slides · Oct 1, 2020
- Q2 2020 Earnings Presentation
Earnings · 17 slides · Aug 4, 2020
- Q1 2020 Earnings Presentation
Earnings · 20 slides · May 5, 2020